Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?

Elisabeth M JongbloedHedwig M BlommesteinHannah M van SchoubroeckJohn W M MartensSaskia M WiltingCarin A Uyl-de GrootAgnes Jager

Published in: Breast cancer (Dove Medical Press) (2023)

The addition of abemaciclib to adjuvant endocrine therapy in all high-risk ER+, HER2- EBC patients is not cost-effective. However, using MRD detection to justify the addition of abemaciclib treatment dominates standard treatment in this cost-effectiveness analysis. Further evaluation of MRD detection in EBC by means of prospective clinical trials assessing clinical utility is recommended and promising in terms of cost-effectiveness.

Keyphrases

end stage renal disease
clinical trial
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
early stage
stem cells
cell therapy
patient reported